Chemo plus immune therapy for HER2-positive advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether adding an immune medicine (an antibody that helps your immune system recognize cancer, such as PD-1) to chemotherapy helps people with advanced HER2-positive non-small cell lung cancer. It may be aimed at people who have never had cancer treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have advanced non-squamous non-small cell lung cancer confirmed by a pathology test (biopsy)
- Your tumor must have HER2 insertion or increased HER2 (amplification)
- You have never had treatment for this cancer before
- Your starting treatment plan must be chemotherapy alone or chemotherapy plus a PD-1 immune antibody
- You should not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
This trial looks at whether adding an immunotherapy drug (an immune checkpoint inhibitor) to chemotherapy helps people with lung cancer live better or respond better. You might be considered if your cancer is confirmed, you can tolerate treatment, and imaging shows measurable spots.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial studies whether giving a PD-1 antibody together with standard chemotherapy before surgery can improve outcomes for people with stage IIIB–IIIC non-small cell lung cancer. It aims to shrink or control the cancer and make treatment before surgery more effective.
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.